Travere Therapeutics, Inc.
TVTX
$33.99
-$1.20-3.41%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 25.71M | -12.76M | -41.23M | -60.26M | -54.81M |
| Total Depreciation and Amortization | 15.79M | 14.02M | 12.80M | 12.09M | 11.24M |
| Total Amortization of Deferred Charges | -- | -- | -- | 1.73M | -- |
| Total Other Non-Cash Items | 10.16M | 9.36M | 9.92M | 3.33M | 7.80M |
| Change in Net Operating Assets | -37.33M | -5.64M | -23.69M | 7.40M | -6.74M |
| Cash from Operations | 14.32M | 4.98M | -42.19M | -35.72M | -42.51M |
| Capital Expenditure | -140.00K | -235.00K | -- | 82.00K | 0.00 |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 86.73M | 5.09M | 41.29M | -80.39M | 46.13M |
| Cash from Investing | 86.59M | 4.85M | 41.29M | -80.31M | 46.13M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -68.90M | -- | -- | -- | -- |
| Issuance of Common Stock | 4.09M | 2.00M | 4.24M | 139.64M | 571.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -525.00K | -525.00K | -525.00K | -525.00K | -525.00K |
| Cash from Financing | -65.34M | 1.48M | 3.72M | 139.12M | 46.00K |
| Foreign Exchange rate Adjustments | 207.00K | 1.95M | 548.00K | -964.00K | 453.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 35.78M | 13.26M | 3.36M | 22.13M | 4.12M |